Buy Mankind Pharma Ltd For Target Rs.3,074 By Geojit Financial Services Ltd
Strong performance across most businesses
Mankind Pharma is an India-based multinational pharmaceutical and healthcare product company, manufacturing antibiotics and gastrointestinal, cardiovascular, dermal and erectile dysfunction medications.
* The company’s consolidated revenue rose 17.3% YoY to Rs. 4,338cr in Q2FY27, supported by strong performance of its domestic formulations business, sustained growth of the Bharat Serums and Vaccines (BSV) specialty segment and healthy momentum in the international business.
* Domestic revenue increased 14.8% YoY to Rs. 3,657cr, driven by chronic therapies, gastro medicines, vitamins and hospital channel expansion.
* International revenue grew 32.7% YoY to Rs. 681cr, led by strong performance of BSV specialty products, US launches and emerging market expansion.
* EBITDA rose 27.2% YoY to Rs. 1,175cr. Also, EBITDA margin expanded 210bps YoY to 27.1%, driven by 90bps gross margin improvement, 40bps lower R&D spend and 80bps operating leverage.
* Reported profit after tax increased 37.7% YoY to Rs. 716cr, aided by stronger EBITDA margin and lower finance costs, partly offset by a higher effective tax rate.
Outlook & Valuation
Mankind Pharma remains focused on broadening its presence across chronic therapies, specialty products and hospital-led channels, supported by its domestic business and growing international operations. In Q2FY27, it continued to scale the BSV business, expand the product portfolio and strengthen its presence in select therapy areas through dedicated divisions. Also, investments in biologics, proprietary R&D and next generation cell therapies through Armed Cell Therapeutics (ACTx) reflect its efforts to diversify beyond traditional pharmaceutical offerings and create long-term growth opportunities. While consumer healthcare performance was subdued, management has initiated corrective measures and highlighted healthy traction in e-commerce channels. Supported by strong BSV execution and a rising chronic mix, we revise our rating to BUY on the stock, based on 42x FY28E P/E, with a revised target price of Rs. 3,074.
Key Concall Highlights
* The share of the chronic portfolio rose 80bps YoY to 37.4% on strong performance in cardiac, anti-diabetes and respiratory therapies. Also, the management reiterated its target of chronic comprising ~50% share of revenue over the next 4-5 years.
* BSV maintained a strong momentum with 20%+ growth for the second consecutive quarter, led by Anti-D (+37%), Humog (+51%), Lonopin (+45%) and Anti-Snake Venom Serum (+45%). * Consumer healthcare was the weak spot, with the management lowering FY27 growth expectations to a high single digit despite market share gains in Manforce and Prega News.
* The company announced the acquisition of a 70% stake in ACTx, gaining access to next-generation CAR-T platforms; committed funding is up to EUR 48mn till FY28.
* The management maintained FY27 EBITDA margin guidance at 25.5-26.5%, despite reporting a stronger Q2FY27 margin of 27.1%.
* FY27 R&D spending is expected to remain at the upper end of the guidance of ~3.0% of revenue, including the impact of the ACTx investment.
* The international business is projected to deliver double digit growth in FY27, supported by BSV specialty products, US launches and emerging market expansion.
* The management reiterated its target of repaying acquisition-related debt by FY28.
For More Geojit Financial Services Ltd Disclaimer https://www.geojit.com/disclaimer
SEBI Registration Number: INH200000345
